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http://dx.doi.org/10.1016/j.stemcr.2016.12.005SUMMARYPatients with glioblastoma die from local relapse despite surgery and high-dose radiotherapy. Resistance to radiotherapy is thought to be
due to efficient DNA double-strand break (DSB) repair in stem-like cells able to survive DNA damage and repopulate the tumor. We used
clinical samples and patient-derived glioblastoma stem cells (GSCs) to confirm that the DSB repair protein RAD51 is highly expressed in
GSCs, which are reliant on RAD51-dependentDSB repair after radiation. RAD51 expression and RAD51 foci numbers fall when these cells
move toward astrocytic differentiation. In GSCs, the small-molecule RAD51 inhibitors RI-1 and B02 prevent RAD51 focus formation,
reduce DNA DSB repair, and cause significant radiosensitization. We further demonstrate that treatment with these agents combined
with radiation promotes loss of stem cells defined by SOX2 expression. This indicates that RAD51-dependent repair represents an effec-
tive and specific target in GSCs.INTRODUCTION
It has beenwidely postulated that a specific sub-population
of glioblastoma (GBM) cells exhibit stem-like properties
and that they underlie treatment resistance and recurrence
due to their ability to survive DNA-damaging treatments
and repopulate the tumor (Mannino and Chalmers,
2011). This population is dynamic and can be altered by
specific growth conditions, including exposure to serum
and bone morphogenic proteins (BMP), which render
them non-tumorigenic (Piccirillo et al., 2006). These cells
cannot be defined by a single marker, but the phenotype
is enriched in Promonin1 (PROM1, known as CD133),
SRY-box2 (SOX2) and Nestin (NES)-positive cells. The role
of individual markers in contributing to the phenotype re-
mains uncertain, but, for example, SOX2 has been func-
tionally implicated in a rapidly proliferating, self-renewing
population, and with maintenance of the undifferentiated
state. Individual markers have rarely been shown to predict
radioresistant sub-populations (Balbous et al., 2014; Bere-
zovsky et al., 2014; Lemke et al., 2014). Upregulated DNA
damage responses (DDRs) have been documented in glio-
blastoma stem cells (GSCs) including enhanced checkpoint
signaling and recruitment of repair proteins (Bao et al.,
2006; Cheng et al., 2011; Facchino et al., 2010; Zeppernick
et al., 2008); however, the mechanisms underlying resis-
tance to treatment are not fully understood. More impor-
tantly, it is not clear how specific resistance mechanisms
align with the established phenotypic characteristics that
drive recurrence or with marker positivity. Therefore, it re-
mains unclear which repair pathways are themost relevant
targets in GSCs.
Overexpression of the DNA repair protein, RAD51, the
central protein involved in homologous repair (HR) ofStem Cell
This is an open access article under the CDNA double-strand breaks (DSBs), has been documented
in glioma and numerous other cancers (Hannay et al.,
2007; Maacke et al., 2000; Mehrara et al., 2007; Tennstedt
et al., 2012; Welsh et al., 2009). Previously, we reported
that targeting RAD51 using small interfering RNA-radio-
sensitized established glioma cell lines, and recent data
confirm that targeting HR is more effective at radiosensitiz-
ing GSCs than inhibiting the major alternative DSB
repair pathway, non-homologous end-joining (NHEJ)
(Lim et al., 2014; Short et al., 2011). Inhibition of HR can
be achieved through modulating expression, inhibiting
nuclear translocation, or preventing DNA binding of
RAD51, and small-molecule inhibitors have been devel-
oped, including B02 and RI-1. B02 impairs the RAD51-sin-
gle-stranded DNA interaction at the primary site of RAD51
during nucleoprotein filament formation and at its second-
ary DNA binding site, where double-stranded DNA at-
taches during the search for homologous DNA (Huang
et al., 2012). This agent displays synergy with the DNA
crosslinking agent cisplatin, which requires HR for DNA
repair (Huang andMazin, 2014). RI-1 possesses a chloroma-
leimide moiety, which covalently binds to the thiol group
in the cysteine at position 319 and occupies the interface
between monomeric RAD51 proteins as well as an ATP
binding loop. This alters RAD51-ATP interactions and sub-
verts RAD51-RAD51 binding and polymerization, which is
essential for filament elongation. RI-1 is synergistic with
mitomycin C and both RI-1 and B02 are radiosensitizers
(Budke et al., 2012a, 2012b; Huang and Mazin, 2014;
Huang et al., 2012; Ward et al., 2015).
In this study, we tested the hypothesis that high RAD51
expression and RAD51 foci activation is specifically associ-
ated with GSCs and that small-molecule inhibitors are
effective GSC radiosensitizers.Reports j Vol. 8 j 125–139 j January 10, 2017 j ª 2017 The Authors. 125
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Figure 1. RAD51 Expression Is Elevated in Patient-Derived Glioma Cells
(A and B) Representative images of immunofluorescence (IF) staining for RAD51 in three GSCs in comparison with normal human as-
trocytes (NHAs) (A), quantified in (B) (n = 6 independent experiments withR100 cells counted per cell line).
(legend continued on next page)
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RESULTS
RAD51 Is Highly Expressed in GSCs
To confirm that RAD51 is a relevant target in GSCs, expres-
sion was examined in patient-derived GSCs and normal
human astrocytes (NHAs). These GSCs are clonogenic cells
propagated as cell lines from freshly resected glioblastoma
tumors. Here, we use GBM1, GBM4, and GBM4UCL that
express high levels of GSC markers NES and SOX2 and
accurately recapitulate GBM when cultured in stem cell-
permissive conditions, as described previously by ourselves
and other authors using comparable protocols (Lee et al.,
2006; Pollard et al., 2009; Wurdak et al., 2010). These cells
maintain distinct morphologies and gene expression pro-
files duringmonolayer culture and form orthotopic tumors
in mice with hallmarks of high-grade brain tumors. Figures
1A–1C show data confirming significantly greater RAD51
expression in all three GSCs compared with NHAs. Using
immunofluorescence (IF) microscopy, 24% (±3%) of NHA
cells were positive for RAD51, compared with 60% ± 3%,
72% ± 4%, and 84% ± 3% of GBM1, GBM4, andGBM4UCL
cells, respectively (n = 6 independent experiments, p <
0.0001). Western blot confirms higher protein levels in
GSCs than NHAs, with very low expression detectable in
NHAs using this assay, which is less sensitive than IF.
RAD51 expression is cell-cycle regulated, being lowest in
resting cells and highest in S and G2 phases (Johnson et al.,
1992; Yamamoto et al., 1996). To establish the contribution
of cell cycling to expression levels, we measured prolifera-
tion and S andG2 phase cell-cyclemarkers. The Ki67 prolif-
eration marker revealed that our GSCs contain >40%–60%
cycling cells, as do NHAs, suggesting that this is not the
explanation for the higher RAD51 levels in GSCs (Figures
S1A and S1B). As we described previously in established
GBM cell lines, the RAD51-expressing cells in the GSC
population are not limited to cells identified by Cyclin A
staining (Short et al., 2011). A significant proportion are
RAD51 positive/Cyclin A negative using IF (Figures S1C
and S1D), indicating that RAD51 expression is not limited
to G2/S phase in GSCs (p < 0.0001). By contrast, in NHAs
the RAD51-positive/Cyclin-A-negative population is very
small, suggesting the expected restriction to G2/S phase.(C) Western blots probed for RAD51 or b-actin in three GSCs and NHA
(D and E) Distributions of RAD51 and SOX2 expression (mRNA levels) i
cells with low and high SOX2 expression.
(F) RAD51 expression levels in SOX2-low (n = 30 cells) and SOX2-high
(G) Representative immunohistochemistry images from patient tumor
or SOX2 (brown) and RAD51 (red) (right hand panels). Examples of ce
negative for both with white arrows, cells positive for just NES or RAD
Student’s t test.
(H) Quantification of RAD51 and stem marker co-expression from ten
Error bars indicate SEM. Statistical significance, unless otherwise stateSince these data suggest significant RAD51 expression in
a high proportion of GSCs, but do not define an association
with any specific sub-population of cells, we investigated
the distribution of RAD51 expression in the GSC popula-
tion further using microfluidics-based single-cell qRT-PCR
analysis. Our data show that RAD51 expression varies,
with a distinctive bimodal distribution of low- andhigh-ex-
pressing cells (Figure 1D). In the same dataset, we defined
the self-renewing fraction by high SOX2 expression, delin-
eated by a minima at a log expression value of 15.6 (Fig-
ure 1E). When we tested the association between SOX2
positivity and RAD51 expression, we found it to be highly
significant (p = 1.28 3 1015), suggesting a correlation be-
tween RAD51 expression and the putative self-renewing
fraction (Figure 1F). We confirmed these data using IF co-
staining for SOX2 and RAD51 (Figure S1E) and also
confirmed co-expression with NES (Figure S1F).
To confirm that RAD51 associates with a poorly differen-
tiated, stem-like, self-renewing population in tumor mate-
rial, ten samples from GBM resections were stained for
RAD51, SOX2, and NES using immunohistochemistry
(Figure 1G). We used c2 tests to assess whether there was
a greater than expected association with RAD51, consid-
ering that NES was detected in 37% of the tumor cells
and SOX2 in 31%. These data show that 61% of RAD51
co-localized with NES, a significant difference from the
expected value (c2, p = 2.1 3 1028). Similarly, 62% of
RAD51 co-localized with SOX2 (c2, p = 1.4 3 1032) (Fig-
ure 1H). These data further confirm that stem cell marker
positivity and high levels of RAD51 are significantly asso-
ciated in GSCs.
RAD51 Expression Is Dependent on Differentiation
Status of GSCs
Because these data suggest that RAD51 may be specifically
expressed in a self-renewing, SOX2-positive sub-popula-
tion in GSCs, we hypothesized that RAD51 expression
may change upon differentiation. To investigate this we
used a forced differentiation paradigm (Piccirillo et al.,
2006; Wurdak et al., 2010; Suva et al., 2014). We first
confirmed that our GSCs responded to exposure to BMP
and serum (fetal bovine serum [FBS]) with loss of stems.
n single GBM1 cells (n = 273 cells). The dotted line in (E) delineates
(n = 243 cells) populations.
samples stained for NES (brown) and RAD51 (red) (left hand panels)
lls positive for both proteins are indicated with black arrows, cells
51 indicated by open arrows. Statistical significance calculated by
tumor samples.
d, calculated by one-way ANOVA. ***p%0.001. Scale bars, 100 mm.
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Figure 2. Differentiation of GBM Stem Lines Causes a Reduction in RAD51 Expression
(A) Immunofluorescence microscopy in three GSCs (GBM1, GBM4, and GBM4UCL) grown in NB medium (untreated) or NB-BMP4-FBS
(treated) and stained for SOX2, NES, and GFAP.
(legend continued on next page)
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cell markers. All three GSCs downregulated NES and SOX2
and upregulated glial fibrillary acid protein (GFAP) within
72 hr following treatment with BMP4 and serum, consis-
tent with Wurdak et al. (2010) (Figures 2A–2C). We note
that upregulation of GFAP was less marked in GBM4UCL,
which is a recognized phenomenon in some cell lines (Re-
strepo et al., 2011). Loss of stem cell markers was associated
with loss of clonogenicity (Figure S2A). We next investi-
gated RAD51 expression in GSCs in response to differenti-
ation cues. Western blots showed a marked reduction in
RAD51 protein expression in all three GSCs following
exposure to serum and BMP4 (Figure 2D). Furthermore,
quantification of IF staining demonstrated a fall in the per-
centage of RAD51-expressing cells, defined by nuclear pos-
itivity, with reductions of 59%, 64%, and 39%, respectively
(59% ± 3% to 24% ± 3% in GBM1, 70% ± 4% to 25% ± 4%
in GBM4, and 80% ± 3% to 49% ± 3% in GBM4UCL, n = 6
independent experiments) (Figures 2E and 2F). Finally,
qRT-PCR analysis revealed downregulation of RAD51
mRNA levels, demonstrating reductions of 53% ± 7%,
85% ± 1%, and 43% ± 12% for GBM1, GBM4, and
GBM4UCL, respectively (n = 3 independent experiments,
p < 0.01) (Figure 2G).
Although differentiation is expected to lead to cell-cycle
exit, it has recently been shown that BMP-directed differen-
tiation does not result in an irreversible G0 state, due to
failed silencing of key cell-cycle and mitosis regulators
(Caren et al., 2015; Dirks, 2008; Wurdak et al., 2010). Inter-
estingly, in two of ourGSCmodels (GBM1 andGBM4UCL),
the changes in RAD51 expression occurred before we could
detect a significant reduction in Ki67 (Figures S2B and
S2C). Although differentiation led to a significant reduc-
tion in Cyclin A positivity, suggesting a shift out of G2/S
phase, there was also a marked reduction in the proportion
of cells that are RAD51 positive/Cyclin A negative (Figures
S2D and S2E). Taken together, these data suggest that
downregulation of RAD51 may occur as part of an early
change in a transcriptional network during differentiation
that is not entirely dependent on cell-cycle exit.
GSC Preferentially Activate RAD51 after Radiation
Damage
To investigate whether changes in RAD51 expression that
occur upon differentiation are associated with a general(B) Mean fluorescence intensity of whole slides from (A) (n = 3 inde
medium (), NB-BMP4-FBS (+).
(C) Western blots probed for SOX2, NES, or GFAP.
(D) Western blots assessing expression of RAD51.
(E) GSCs grown in NB medium (untreated) or NB-BMP4-FBS (treated)
(F) Quantification of RAD51 expression from (E) (n = 6 independent
(G) qRT-PCR of RAD51 mRNA in GSC cultured in NB medium () or NB
Error bars indicate SEM. Statistical significance was calculated usingdownregulation of DSB repair protein activity, we
measured levels of other proteins including PRKDC
(DNA-PKcs), XRCC5 (Ku80), and XRCC6 (Ku70). No signif-
icant changes were observed in expression of any of these
proteins in GSCs in response to differentiation conditions,
and all are expressed in NHAs (Figure 3A).
To confirm that RAD51 was functional in these cells, we
next examined foci formation in the presence or absence
of BMP4/serum 4 hr after 3 Gy X-ray. The resulting data
showed a robust increase in RAD51 foci numbers in
GSCs after XR that is attenuated when GSCs are exposed
to FBS and BMP4 for 72 hr (Figures 3B and 3C). More
detailed analysis of RAD51 foci kinetics in GBM1
confirmed lower foci numbers in differentiated cells over
a repair time course of 24 hr (Figure S3A). Since this sug-
gests that differentiation is associated with both a change
in RAD51 expression and reduced activation at repair foci,
we next measured TP53BP1 foci formation, which marks
DSB for repair by NHEJ, primarily by blocking end resec-
tion (Callen et al., 2013; Chapman et al., 2012, 2013;
Xie et al., 2007). Thirty minutes after irradiation, we
observed higher numbers of TP53BP1 foci per cell in all
three GSCs exposed to serum and BMP4, compared with
cells in standard growth conditions (Figures 3D and 3E).
These data were also confirmed by examining foci over
a 24 hr repair time course in GBM1 cells (Figure S3B).
A comparison of DSB repair kinetics using gH2AX foci
demonstrated that GSC in stem cell-permissive or differ-
entiating conditions had slower repair kinetics than
NHAs, with more residual unrepaired DSB at 24 hr
(Figure S3C). A detailed comparison at 24 hr post-irradia-
tion in all three GSCs demonstrated that the serum/
BMP4-treated cells have more residual unrepaired DSB
(Figures 3F and 3G), despite there being no differences
in initial foci numbers (Figure S3C), implying less efficient
repair.
These data suggest that differentiation does not cause a
global change in levels of DNA DSB repair proteins, but
rather that GSCs in stem cell conditions preferentially
upregulate RAD51 and activate RAD51 foci at sites of
damage, whereas in differentiating conditions, GSCsmain-
tain lower RAD51 protein levels, show less activation of
RAD51 foci at sites of damage, and preferentially activate
TP53BP1 foci.pendent experiments withR100 cells counted per condition). NB
, stained for RAD51 and visualized by IF microscopy.
experiments withR100 cells counted per cell line).
-BMP4-FBS (+) (n = 3 independent experiments).
one-way ANOVA with **p < 0.01, ***p < 0.001. Scale bars, 20 mm.
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Figure 3. Differentiation Alters the Ability of GBM Stem Lines to Repair DNA Damage Caused by Ionizing Radiation
(A) Western blots probed for PRKDC or XRCC5/XRCC6 (Ku80/Ku70) in GSC grown in NB medium or NB-BMP4-FBS. b-Actin or Vinculin was a
loading control. HeLa included as positive control and NHA for comparison.
(legend continued on next page)
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RAD51 Inhibitors Radiosensitize GSCs
Because these data confirmed that RAD51 may be a partic-
ularly relevant target in GSCs, the effect of combining
small-molecule RAD51 inhibitors with radiation was
investigated.
Figure 4A shows the clonogenic survival data for the
three GSCs treated with RI-1 (1.5 mM), B02 (1.2 mM), or
DMSO and radiation doses between 1 and 5 Gy. The
mean inactivation dose (MID, dose causing 50% cell death)
and dose-modifying factors (DMF, ratio of untreated to
treated MID, where values >1 indicate radiosensitization)
were calculated by fitting the data to the linear-quadratic
model (Hall and Giaccia, 2006). In GBM1, an MID of
2.69 Gy in cells exposed to XR only was reduced to 1.94
and 1.87 Gy after treatment with RI-1 or B02, respectively
(DMFs of 1.39, 1.44). Similar effects were observed in
GBM4 cells (DMF of 1.43, 1.55) and GBM4UCL (DMF of
1.54 and 1.70). Comparison of survival curves by two-
way ANOVA demonstrated that, for each cell line, treat-
ment with either inhibitor resulted in a statistically signif-
icant difference in survival compared with untreated
cells (p < 0.001 in each case). These data confirm radiosen-
sitization in GSCs using either of the small-molecule
RAD51 inhibitors (RI-1 or B02).
To confirm that RI-1 and B02 were directly affecting DNA
repair as predicted by their known mechanisms of action,
RAD51 and gH2AX foci were assessed in irradiated and
RAD51 inhibitor-treated cells. Treatment of GSCs with
either agent reduced RAD51 foci formation post-irradiation
(4 hr, 3 Gy) by >75% in all three cell lines (Figures 4B and
4C) and consistently increased numbers of gH2AX foci at
24 hr, with no effect on foci induction at early time points
(30 min), indicating a reduced DSB repair capacity (Figures
4D, 4E, S4A, and S4B). By contrast in NHAs, the RAD51
inhibitors did not affect the number of gH2AX foci at
24 hr (Figures S4C and S4D), suggesting no effect on repair
capacity.
To confirm that these inhibitors caused additional
cytotoxicity when used in combination with radiation,
apoptosis was measured 5 days after treatment using An-
nexin V/propidium iodide (PI) labeling. The results showed
an increase in both early apoptotic (Annexin V positive)
and apoptotic cells (Annexin V and PI positive) following
treatment of GBM1 with either RAD51 inhibitor (Fig-(B) Representative images of RAD51 foci in the nuclei of GSCs grown i
radiation.
(C) Quantification of RAD51 foci from (B) (n = 3 independent experim
(D) Representative images of GSC nuclei stained for TP53BP1 foci 30
(E) Quantification of TP53BP1 foci from (E) (n = 6 independent expe
(F) Representative images of GSC nuclei stained for gH2AX 24 hr foll
(G) Quantification of gH2AX foci from (F) (n = 3 independent experim
Error bars indicate SEM. Statistical significance was calculated usingure 4F). A 1.8-fold increase in apoptotic cells was observed
with either RI-1 or B02 (p < 0.0001). Early apoptotic cells
were increased 1.67- and 1.61-fold with RI-1 and B02,
respectively (p < 0.05). Similar results were obtained in
GBM4 and GBM4UCL cells (Figures S4E and S4F).
Taken together, these data suggest that GSCs are radio-
sensitized by small-molecule RAD51 inhibitors, consistent
with a significant reliance on RAD51-dependent repair
events after irradiation.
Since neither of the RAD51 inhibitors are suitable for
treating intracranial tumors, the established U87 glioma
cell line was implanted as a subcutaneous xenograft and
used as amodel to test the effects of radiation ±RI-1 in vivo.
Although these cells do not express high levels of conven-
tional stem cell markers, they do express high levels of
RAD51 required for this approach to radiosensitization
(Short et al., 2011). The effects of RI-1 and B02 on U87
were first confirmed in vitro, demonstrating that the inhib-
itors reduced the number of RAD51 foci and radiosensi-
tized the cells (Figure S5). Xenografts were treated in four
groups: control, radiotherapy only, RI-1 only, and RI-1
combined with radiotherapy. Radiotherapy was delivered
in 33 5 Gy fractions on alternate days with RI-1 or vehicle
delivered intratumorally 3 hr before irradiation. Tumor
growth was recorded over time, normalized to volumes at
day 0 and log-transformed to allow for fitting of data using
linear regression (Figure 4G). The linear regression of the
increase in tumor volumewas used to determine the tumor
growth rate, fromwhich doubling time (DT) was calculated
(Demidenko, 2010). The DTwas 3.85 days for vehicle-only-
treated tumors, 5.61 days for RI-1, 7.16 days for radio-
therapy only, and 11.1 days for the combination of RI-1
and radiotherapy. All treatments caused a significant in-
crease in DT when compared with control, and the combi-
nation of both treatments significantly enhanced growth
retardation (p < 0.0001) compared with either treatment
individually. These data confirm a radiosensitizing effect
of pharmacologic inhibition of RAD51 in vivo.
Combination Treatment with Radiation and a RAD51
Inhibitor Results in Loss of the SOX2+ Clonogenic
Population
Since we have shown that inhibiting RAD51 is an effective
means of radiosensitizing GSCs and that there is an either NB medium or NB-BMP4-FBS, 4 hr after treatment with 3 Gy
ents withR100 cells counted per condition).
min post-treatment with 3 Gy radiation.
riments withR100 cells counted per condition).
owing 3 Gy radiation.
ents withR100 cells counted per condition).
one-way ANOVA with ***p < 0.001. Scale bars, 20 mm.
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significant association between RAD51 expression and
SOX2 expression, we further hypothesized that targeting
RAD51 repair may specifically remove SOX2 and RAD51
double-positive cells, potentially removing a radioresist-
ant, self-renewing cellular fraction.We therefore examined
the expression of both genes in singleGSCs before and after
exposure to radiation (2 Gy), in the presence or absence of
the RAD51 inhibitor RI-1 (1.5 mM). We measured expres-
sion of RAD51 and SOX2 mRNA 1 and 3 weeks post-treat-
ment, including the time point at which apoptosis occurs
in response to treatment (1week) andwhenmost cell death
has occurred, leaving a population that has survived treat-
ment (3 weeks).
The distributions of RAD51 single-cell expression data
are shown as bean plots for each treatment condition in
Figure 5A, and demonstrate a major sub-population with
high expression and a second population with lower,
more variable expression in all conditions, as demonstrated
previously (Figure 1D). In contrast, all cells express high
levels of SOX2 (Figure 5B). In untreated cells, there is no
change in the distribution of RAD51 expression at either
1 or 3 weeks (Figure 5A, first column), but a slight increase
in SOX2 is observed at 3 weeks, whichmay be explained by
overgrowth by SOX2+ cells in permissive culture condi-
tions (Figure 5B, first column). Treatment with a single
dose (2 Gy) of radiation does not affect the expression of
RAD51 or SOX2 (Figures 5A and 5B, second columns), sug-
gesting that this population is stable over the course of this
experiment and not affected by XR. In contrast, exposure
to the RAD51 inhibitor RI-1 alone causes a marked shift
in the distribution for both RAD51 and SOX2 after 1 week
(Figures 5A and 5B; third columns). There is a fall in the
proportion of cells with high RAD51 expression and reduc-
tion in median expression levels (from 6.1 ± 0.5 in un-
treated cells to 2.7 ± 0.4 in RI-1-treated cells; p < 0.0001,
n = 92 cells). Similarly, SOX2 expression is reduced acrossFigure 4. RAD51 Inhibitors Radiosensitize Cells Expressing High
(A) Clonogenic survival of GSCs treated with DMSO, RI-1 (1.5 mM), or
5 Gy). Data were fitted using the linear-quadratic model and statistic
experiments).
(B) IF microscopy staining for RAD51 in three GSCs showing the eff
treatment with 3 Gy radiation.
(C) Quantification of RAD51 foci in (B) (n = 3 independent experime
(D) Effect of RAD51 inhibitors (30 mM RI-1 or B02) or BMP4 (10 ng/mL)
24 hr after treatment with 3 Gy radiation.
(E) Quantification of gH2AX foci from (D) (n = 3 independent experi
(F) Annexin V/PI staining of GBM1 cells treated with B02 or RI-1 (7.5
for 5 days prior to staining. Statistical significance in (C), (D), an
experiments).
(G) Log-transformed tumor growth data from untreated mice, mice trea
(15 Gy in 33 5 Gy) on alternate days alone, or mice treated with a com
Statistical significance was determined by one-way ANOVA. For all pan
combination compared with individual treatments. Scale bars, 20 mmthe entire population with the median level falling from
15.8 ± 0.3 in untreated cells to 13.7 ± 0.3 (p < 0.0001,
n = 92–96 cells). However, this effect is transient, and by
3 weeks after treatment the distribution of RAD51 expres-
sion is not significantly different from untreated controls
(median expression 5.7 ± 0.7 in untreated cells and 4.9 ±
0.5 in RI-1-treated cells; p > 0.05, n = 92 cells). SOX2 expres-
sion has also recovered significantly at 3 weeks, although it
remains lower in cells exposed to RI-1 compared with un-
treated controls (median levels 17.3 ± 0.1 [untreated] and
16.1 ± 0.1 [RI-1]; p < 0.0001, n = 92–96 cells). These data
are consistent with early toxicity and apoptosis of cells
with high RAD51 expression, followed by replacement of
this population.
Remarkably, combining RI-1 treatment with radiation
has a dramatically different effect than RAD51 inhibition
alone. After 1 week, the distribution of both RAD51 and
SOX2 expression is no different to untreated cells (Figures
5A and 5B, fourth columns). This is in marked contrast to
the downregulation seen on exposure to RI-1 alone, indi-
cating that radiation has abrogated the effects of the
RAD51 inhibitor at this time point. However, by 3 weeks
post-treatment, a very different population emerges
with significantly reduced SOX2 expression (median level
11.4 ± 0.1, compared with 17.3 ± 0.1 in untreated cells;
p < 0.0001, n = 92 cells). Within this population, the
bimodal distribution of RAD51 is maintained, but expres-
sion levels have increased (median expression is 9 ± 0.6
versus 5.7 ± 0.7 in untreated cells at 3 weeks, 5.7 ± 0.7;
p < 0.0001, n = 92 cells). We examined SOX2 expression
specifically in cells expressing either low or high levels
of RAD51 and confirmed that, 3 weeks after combined
radiation and RI-1 treatment, SOX2 is significantly lower
in both populations (Figure 5C). These cells are non-
clonogenic (plating efficiency [PE] 0, compared with
control PE 0.36, SD 0.09), indicating a redistribution ofRAD51 In Vitro and In Vivo
B02 (1.2 mM) in combination with radiation (doses between 0 and
al significance determined by two-way ANOVA (n = 3 independent
ect of RI-1 and B02 (30 mM) on number of RAD51 foci 4 hr after
nts withR100 cells counted per treatment).
+ FBS (10%) on gH2AX foci (as visualized by IF microscopy) in GSCs
ments withR100 cells counted per treatment).
mM) 24 hr prior to irradiation (2 Gy) followed by incubation at 37C
d (F) was calculated using one-way ANOVA (n = 3 independent
ted with RI-1 (100 mL of 20 mM RI-1), or mice treated with radiation
bination of RI-1 and radiation (n = 10 animals per treatment group).
els, error bars indicate SEM, *p< 0.05, ***p < 0.001, ###p < 0.001 for
.
Stem Cell Reports j Vol. 8 j 125–139 j January 10, 2017 133
Figure 5. Combined Treatment with RAD51 Inhibitor and Radi-
ation Results in Loss of the SOX2-Positive Clonogenic Population
(A) Bean plots illustrating expression of RAD51 mRNA (Log2(Exp))
in single cells cultured in a clonogenic assay, with and without
134 Stem Cell Reports j Vol. 8 j 125–139 j January 10, 2017population dynamics toward cells with low self-renewing
capacity.
Overall, these data show the potential for recovery in
GSCs that express RAD51 and SOX2 after XR treatment,
since after 2 Gy both of these populations persisted, con-
firming their contribution to the surviving population.
Our data suggest that although RI-1 significantly reduced
the RAD51-expressing population of cells 1 week after
exposure, combining RI-1 with XR annulled this effect
and, by 3 weeks, the RAD51-expressing population re-
emerged in both treatment conditions. However, they
also suggest a significant effect of combined treatment
with XR and RI-1 on the SOX2-expressing population,
which does not re-emerge after combination treatment.
These data demonstrate the potential for abolishing clono-
genicity by combining RI-1 with radiation.DISCUSSION
Identifying targets in the DDR pathway as a means to
sensitize cancers to DNA-damaging cytotoxic treatments
including radiotherapy has become of increasing interest
with the availability of new inhibitors and the demonstra-
tion of their effectiveness in specific contexts. A notable
example is the use of PARP inhibitors in BRCA-deficient tu-
mors, based on the synthetic lethality paradigm (Audeh
et al., 2010; Helleday, 2011; Tutt et al., 2010). In glioma, at-
tempts to improve the outcome by adding agents to in-
crease radiation sensitivity have been the subject of much
research, but none of these approaches have been success-
ful. The stem cell model has added a new perspective to
these investigations, since GSCs are believed to be theradiation (2 Gy) exposure and/or RI-1 (1.5 mM), harvested at 1
or 3 weeks. Black lines show the median expression, each white
line represents a single cell, and the width of the bean indicates
the density of single cells with specific expression levels. UT,
untreated.
(B) Bean plots illustrating expression of SOX2 mRNA (Log2(Exp))
in single cells cultured in a clonogenic assay, with and without
radiation (2 Gy) exposure and/or RI-1 (1.5 mM), harvested at 1 or
3 weeks.
(C) Boxplot to demonstrate levels of SOX2 mRNA expression in
RAD51 low- and high-expressing GBM1 cells at 1 and 3 weeks after
treatment with radiation and RI-1.
Error bars indicate SEM. For comparisons between time points,
statistical significance was calculated using the Student’s t test for
each treatment (*p < 0.05, ***p < 0.001). For comparisons be-
tween treated and untreated cells, statistical significance was
calculated using one-way ANOVA (###p < 0.001). For each treat-
ment, 96 cells were captured and cDNA amplified on a single 96.96
Dynamic Array IFC. Number of cells for which data was obtained are
mentioned in the text.
relevant target population. However, specific repair targets
have not been linked with this cell population. In this
study, we demonstrated that RAD51 and the HR pathway
represent a specific DNA repair target in GSC.
We first demonstrated that GSCs express high levels of
RAD51 and that this is associated with robust foci forma-
tion after irradiation. This is surprising since in most cir-
cumstances HR is responsible for a small fraction of DSB
repair. However, the complex regulation of the balance
between repair pathways is still not fully understood and
hyper-recombination with significant utilization of HR
documented in tumor cell lines may be associated with
loss of normal TP53 function, which can increase HR by
promoting BRCA1 binding at DSBs (Dong et al., 2015).
We further show that RAD51 expression is associated
with markers of stemness both in vitro and in tumor
material, and that a forced differentiation paradigm using
BMP4/FBS reduces this expression within 72 hr. It has
recently become clear that this manipulation is not equiv-
alent to terminal differentiation and that associated
changes in DNA methylation, chromatin structure, and
transcription occur with variable and often delayed ki-
netics. Interestingly a failure to repress SOX2-driven tran-
scription programs is suggested to be an important influ-
ence on the ability of these cells to re-enter the cell cycle
(Caren et al., 2015). The transcriptional programs that un-
derlie these changes, including those that may explain the
close correlation between SOX2 and RAD51 expression are
the subject of ongoing research. Interestingly, recent data
suggest that SOX2 and RAD51may be regulated by overlap-
ping transcription factors, including FOXM1 (Lee et al.,
2015; Zhang et al., 2012).
The data presented here also demonstrate that inhibiting
RAD51 is an effective means of sensitizing GSCs, as would
be predicted from evidence that RAD51 is very active in
contributing to DNA repair in these cells. This is consistent
with previous data specifically examining the role of HR in
GSCs (Lim et al., 2012, 2014) but may also explain the
important contribution of cell-cycle checkpoint upregula-
tion to resistance in these cells since homology-directed
repair has a long half-time (Jeggo et al., 2011; Qin et al.,
2014).
Whenwe examined ourGSCs following treatmentwith a
RAD51 inhibitor and radiation, we found that, contrary to
our expectations, a RAD51-expressing population reap-
peared after treatment and that exposure to XR seemed to
enhance this. Fascinatingly, however, combination treat-
ment was effective in removing the SOX2-expressing popu-
lation and rendered surviving cells non-clonogenic. The
exact mechanisms that explain sensitivity to XR combined
withRAD51 inhibition in these cells and the associationbe-
tween RAD51 expression and surviving, non-clonogenic
cells after XR requires further investigation. Nevertheless,our study provides a strong rationale for targeting RAD51-
mediated repair to specifically radiosensitize GSCs.EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
GBM1 and GBM4 (a gift from H. Wurdak) were maintained as
described previously (Wurdak et al., 2010). They were cultured in
Neural Basal medium consisting of NeurobasalMedium (Life Tech-
nologies), N2 and B27 supplements (Life Technologies, 0.53 each),
recombinant basic fibroblast growth factor (bFGF), and epidermal
growth factor (EGF) (Peprotech and R&D Systems, respectively,
40 ng/mL). GBM4UCL cells (a gift from S. Brandner, UCL Institute
of Neurology) were cultured in DMEM/F12 (1:1 mixture), with
15 mM HEPES and 2 mM L-glutamine (Sigma), 13 B27, and
20 ng/mL each of recombinant EGF and bFGF. GSCs were cultured
on laminin-coated (2 mg/mL; Sigma-Aldrich) surfaces. NHAs were
purchased from Lonza and grown in AGM astrocyte growth me-
dium (Lonza). U87-MG (ECACC) cells were grown in DMEM sup-
plemented with 2mML-glutamine (Sigma) and 10% FBS (Biosera).
BMP4 was obtained from Life Technologies. Protease inhibitor
cocktail and trypsin were purchased from Sigma-Aldrich. The
RAD51 inhibitors B02 and RI-1 were purchased from Sigma-
Aldrich and Merck, respectively, and stored as 10 mM stock solu-
tions in DMSO.Immunofluorescence Microscopy
Cells were cultured on laminin-coated coverslips, fixed in 4% para-
formaldehyde (PFA), and blocked with blocking buffer (10% FBS,
0.2% Triton X-100, and 0.1% sodium azide in PBS) for 2 hr at
room temperature (RT). Cells were incubated with primary anti-
body overnight at 4C in a humidified chamber. The antibodies
used were anti-RAD51 (1:1,000) and anti-gH2AX (1:800) (PC130,
JBW130, respectively; Merck), anti-SOX2 (1:50) and anti-nestin
(1:1,000) (MAB2018, MAB1259, respectively; R&D Systems), and
anti-TP53BP1 (ab36823, 1:1,000; Abcam). After washing (3 3
5 min in PBS), cells were incubated with secondary antibodies
(donkey anti-rabbit-Cy3, 711165152, Jackson ImmunoResearch;
and goat anti-mouse-Alexa 488, A11029, Life Technologies,
1:1,000) for 1 hr at RT. The cells were then washed in PBS with
DAPI (0.1 mg/mL; Biotium) andmounted on glass slides with Fluo-
romount-G (SouthernBiotech). Cells were viewedusing aNikonA1
confocal microscope and images analyzed in Fiji (Schindelin et al.,
2012). For the detection of RAD51, background fluorescence
(determined from secondary AB-only controls) was subtracted
and any cell with detectable fluorescence in the nucleuswas scored
positive. Foci were counted manually with a minimum of 50 cells
scored per condition.Western Blotting
Whole-cell extracts were prepared in radioimmunoprecipitation
assay buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS,
and protease inhibitor cocktail), fractionated by SDS-PAGE, and
transferred to a nitrocellulose membrane according to the manu-
facturer’s instructions (Invitrogen). Membranes were blocked
with LI-COR blocking buffer (LI-COR Biosciences) and incubatedStem Cell Reports j Vol. 8 j 125–139 j January 10, 2017 135
with antibodies against RAD51 (D4B10, 1:1,000; Cell Signaling
Technology), SOX2 (1:1,000) and nestin (1:1,000) (MAB2018,
MAB1259, respectively; R&D Systems), GFAP (Z0334, 1:100;
Dako), b-actin (ab8227, 1:20,000), PRKDC (ab32566, 1:5,000),
XRCC5/XRCC6 (Ku80/Ku70) (ab53126, 1:100,000), and vinculin
(ab129002, 1:20,000) (all from Abcam). Antibody binding was
visualized by: (1) incubation with Alexa Fluor 680-conjugated sec-
ondary anti-mouse/rabbit antibodies (1:5,000; Life Technologies)
and imaged on an Odyssey Infrared Imaging System (LI-COR Bio-
sciences) or (2) using a SuperSignal West Pico Complete Mouse/
Rabbit IgG Detection Kit (Thermo Fisher Scientific) according to
the manufacturer’s instructions, imaging with X-ray film.
Quantitative Real-Time PCR
Total cellular RNA was extracted from cells 48 hr after seeding
using RNeasy Mini Kit (QIAGEN) according to the manufacturer’s
instructions. Reverse transcription of approximately 400–800 ng
of total RNA was carried out to obtain cDNA as described previ-
ously (Burchill et al., 1994). For quantitative real-time RT-PCR
analysis, cDNA was added to 20 mL of PCR mix to produce a 13
TaqMan Universal PCR Master Mix (containing AmpliTaq Gold
DNA Polymerase; Life Technologies) with a 13 RAD51 or b-actin
TaqMan Gene Expression Assay (Life Technologies) in RNase-
free H2O. Samples were analyzed using an Applied Biosystems
7500 Real-Time PCR instrument. Ct values for candidate genes
were normalized to the mean Ct values for b-actin for both test
and control samples. The resulting test values were normalized
to control samples.
Single-Cell Experiments
GBM1 cells were seeded into 6-well plates (500–1,500 cells/well)
and untreated or treated with 2 Gy radiation, RI-1 (1.5 mM), or
RI-1 and 2 Gy radiation, and then incubated for 1–3 weeks at
37C. Cells were harvested by trypsinization and resuspended in
culture medium at 2.5 3 105 cells/mL. Cells were diluted in C1
cell suspension reagent at a ratio of 3:2, respectively. Single cells
were captured onto a medium (10–17 mM) C1 Single-Cell Auto
Prep IFC for PreAmp according to the manufacturer’s instructions
using the Fluidigm C1 Single-Cell Auto Prep System (Fluidigm).
Preamplification was conducted using pooled TaqMan primers
(180 nM) for the targets of interest (Life Technologies). Amplified
products were diluted with C1 DNA dilution reagent (25 mL) and
stored at 20C until use. Bulk tube controls were prepared from
the remaining GBM1 cells according to themanufacturer’s instruc-
tions. Single-cell cDNAwas amplified for the genes of interest on a
96.96 Dynamic Array IFC using the Fluidigm Biomark system.
Gene expression was analyzed using Fluidigm analysis software.
Log2(Exp) expression values were calculated by subtracting the in-
dividual Ct values from 30. A Ct value of 30 was used as the limit of
detection for the assays. BoxPlotR software was used to generate
bean plots of the Log2(exp) values. R was used to generate density
and boxplots. SINGuLAR Analysis Toolset was used to calculate
significance between treatment groups.
Immunohistochemistry
Tumor samples were collected from consenting patients undergo-
ing surgery at the Leeds Teaching Hospitals NHS Trust in accor-136 Stem Cell Reports j Vol. 8 j 125–139 j January 10, 2017dance with local ethics. Samples were fixed for 24 hr in 4% PFA
at 4C and transferred to 70% ethanol before embedding in
paraffin. Tumor sections (5 mm) were mounted onto Superfrost
Plus slides (Thermo Fisher Scientific). Dewaxing and antigen
retrieval was performed using MenaPath slide wash and access
EDTA (pH 8.5–8.7) in a pressure cooker. Slides were incubated
with 3% hydrogen peroxide for 20 min to block endogenous
peroxide. Slides were mounted in Sequenza racks, washed with
Tris-buffered saline (TBS) and blocked with casein-blocking solu-
tion (Vector) for 30min at RT. Antibodies to RAD51 (E19100 Spring
Bioscience, 1:75), SOX2, and NES (MAB2018; 1:800, MAB1259;
1:10,000, respectively; R&D Systems) were incubated with the
slides overnight at 4C.After washingwithTBS, the cells were incu-
bated with an X-Cell Plus multiplex HRP-ALP Kit (MenaPath) for
30 min. Bound antibodies were visualized with Vulcan Fast Red
chromogen or diaminobenzidine (MenaPath) for rabbit and
mouse antibodies, respectively, before counterstaining with hema-
toxylin, dehydration, and mounting with coverslips. Slides were
scanned on anAperio ScanScopeATslide scanner (Leica), tumor re-
gions were manually annotated, and 100 sub-regions for analysis
randomly assigned using RandomSpot (Wright et al., 2015). Image
patches were extracted using the coordinates in the annotated
XML files. Extracted images were split into separate staining chan-
nels using color deconvolution, which were individually thresh-
olded into foreground and background components using Otsu’s
bimodal histogram method. The two resulting masks were then
used to determine the amount of staining present for each stain.
Using the spatial distribution of both masks, the intersection of
each channel was calculated in order to identify the level of co-
localization of stains. The presence of stains was reported as a per-
centage of pixels within the staining channel masks in relation to
the total number of pixels in the image.Clonogenic Survival Assay
Clonogenic survival assays were carried out as described previously
(Franken et al., 2006). In brief, cells were seeded into 24-well plates
at 125 cells/well in medium containing the appropriate treatment
and incubated for 2 hr at 37C before irradiation. The cells were
returned to the incubator for 3 weeks. Cells were fixed with 4%
PFA for 15 min and stained with methylene blue (1%, w/v, 50%,
v/v, ethanol) for 30 min. After washing in water the colonies
were counted using a Gallenkamp colony counter. Data were
analyzed in Prism using the LQ model of radiation survival
described by the equation S = exp(ad  bd2), where S is the sur-
vival fraction, d is the XR dose, and a and b are constants (Douglas
and Fowler, 1976).Annexin V/PI Assay
Cell killing was determined using the BD Biosciences FITC
Annexin V Apoptosis Detection Kit II according to the manu-
facturer’s instructions. Cells were seeded at 5 3 104 cells/well in
a 24-well plate and incubated at 37C. After 24 hr, the cells
were treated with RI-1 or B02 at 7.5 mM for a further 24 hr
and then irradiated with 2 Gy. The cells were returned to
the incubator for 5 days then harvested and stained using an
FITC Annexin V Apoptosis Detection Kit II and analyzed on an
Applied Biosystems Attune acoustic focusing cytometer. Data
were analyzed using Attune software. Unstained cells were
considered live, Annexin V-positive cells were designated to be
early apoptotic, PI-only-positive cells necrotic, and double-posi-
tive cells apoptotic.
In Vivo Studies
Animals were purchased from the breeding facility, University of
Leeds. U87-MG cells (1 3 106), in 50 mL of PBS, were injected sub-
cutaneously into the right flank of 7–9-week-old female BALB/c
nude mice. Once tumors were palpable (approximately 5 mm
diameter), animals were randomly assigned into experimental
groups. Treatment consisted of three cycles over 5 days. RAD51 in-
hibitor RI-1 was administered at a concentration of 20 mM in a so-
lution of 30% DMSO, 35% PEG 400, and 35% PBS. On each treat-
ment day, animals received intratumoral injections of 100 mL of
PBS/DMSO/PEG 400 solution (control) or 20 mMRI-1. Three hours
after injection, animals were either mock irradiated (anesthetized
but not irradiated) or received image-guided radiotherapy deliv-
ered by SARRP (XStrahl). For each treatment, a dose of 5Gywas tar-
geted to the tumor using a 10 3 10 mm collimator and two
opposing beams. After treatment, animal welfare was monitored
daily, and tumors weremeasured three times a week using calipers.
Animals were killed once tumors attained a mean diameter of
12.5 mm. Tumor volumes were calculated using (a2b)/2, where a
and b represent the smallest and largest dimensions of the tumor,
respectively. Tumor growth rate was determined as described by
Demidenko (2010). Plotting the natural log of tumor volume
against time gives a straight line described by the equation lnV =
a + bt, where V is the tumor volume, a is the y intercept (tumor
starting volume), b is the growth rate, and t is the time. Tumor
DT was calculated using DT = ln2/b (Demidenko, 2010; Mehrara
et al., 2007). All experiments were performed in accordance with
the Animals (Scientific Procedures) Act 1986, under license num-
ber 70/7340.
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